New Data from Phase 3 PAPILLON Study Show RYBREVANT®▼ (amivantamab) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lu
Oncology
New Data from Phase 3 PAPILLON Study Show RYBREVANT®▼ (amivantamab) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lu
